Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Platelet Transfusion | 5 | 2018 | 209 | 2.13 | Why? |
| Blood Preservation | 3 | 2018 | 191 | 1.39 | Why? |
| Erythrocyte Transfusion | 4 | 2018 | 386 | 0.92 | Why? |
| Fibrinogen | 2 | 2017 | 1048 | 0.87 | Why? |
| Blood Transfusion | 5 | 2020 | 1399 | 0.72 | Why? |
| Drug Storage | 1 | 2018 | 125 | 0.69 | Why? |
| Coagulants | 1 | 2017 | 30 | 0.68 | Why? |
| Hemorrhage | 9 | 2021 | 3013 | 0.66 | Why? |
| Blood Platelets | 2 | 2018 | 1704 | 0.63 | Why? |
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 176 | 0.58 | Why? |
| Iatrogenic Disease | 1 | 2017 | 304 | 0.53 | Why? |
| Erythrocytes | 1 | 2018 | 617 | 0.47 | Why? |
| Blood Component Transfusion | 1 | 2017 | 740 | 0.46 | Why? |
| Blood Safety | 3 | 2020 | 459 | 0.37 | Why? |
| Australia | 8 | 2020 | 6306 | 0.29 | Why? |
| Transfusion Reaction | 2 | 2017 | 245 | 0.28 | Why? |
| Wounds and Injuries | 2 | 2017 | 1708 | 0.28 | Why? |
| Blood Banks | 2 | 2020 | 535 | 0.27 | Why? |
| Critical Illness | 6 | 2021 | 17281 | 0.24 | Why? |
| Randomized Controlled Trials as Topic | 9 | 2021 | 10649 | 0.23 | Why? |
| Treatment Outcome | 11 | 2021 | 51732 | 0.21 | Why? |
| Agglutination Tests | 1 | 2020 | 124 | 0.20 | Why? |
| Hospital Mortality | 5 | 2021 | 22087 | 0.20 | Why? |
| Multiple Myeloma | 2 | 2019 | 1064 | 0.18 | Why? |
| Antifibrinolytic Agents | 1 | 2019 | 150 | 0.18 | Why? |
| Tranexamic Acid | 1 | 2019 | 121 | 0.18 | Why? |
| Heparin | 2 | 2021 | 2600 | 0.18 | Why? |
| Afibrinogenemia | 1 | 2017 | 10 | 0.18 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1573 | 0.17 | Why? |
| Victoria | 2 | 2017 | 607 | 0.17 | Why? |
| Bacteriuria | 1 | 2017 | 31 | 0.17 | Why? |
| New Zealand | 3 | 2020 | 2073 | 0.16 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.16 | Why? |
| Nurse-Patient Relations | 1 | 2018 | 168 | 0.16 | Why? |
| Agammaglobulinemia | 1 | 2019 | 213 | 0.16 | Why? |
| Immunization, Passive | 6 | 2021 | 10067 | 0.15 | Why? |
| Neoplasm Grading | 1 | 2017 | 400 | 0.15 | Why? |
| Hematology | 2 | 2020 | 649 | 0.15 | Why? |
| Antibiotic Prophylaxis | 1 | 2019 | 399 | 0.15 | Why? |
| Hemostatics | 1 | 2017 | 142 | 0.15 | Why? |
| Non-Randomized Controlled Trials as Topic | 3 | 2021 | 220 | 0.15 | Why? |
| Hematologic Neoplasms | 2 | 2019 | 2105 | 0.15 | Why? |
| Injury Severity Score | 1 | 2016 | 287 | 0.15 | Why? |
| Cause of Death | 5 | 2021 | 4823 | 0.14 | Why? |
| Rivaroxaban | 1 | 2018 | 467 | 0.14 | Why? |
| Fibrinolysis | 1 | 2019 | 521 | 0.14 | Why? |
| Immunoglobulins | 1 | 2020 | 811 | 0.14 | Why? |
| Myelodysplastic Syndromes | 1 | 2017 | 261 | 0.14 | Why? |
| Intensive Care Units | 3 | 2020 | 29594 | 0.13 | Why? |
| Complement System Proteins | 1 | 2017 | 380 | 0.13 | Why? |
| Logistic Models | 3 | 2021 | 9089 | 0.13 | Why? |
| Zika Virus Infection | 2 | 2017 | 1920 | 0.13 | Why? |
| Communicable Diseases, Emerging | 2 | 2017 | 2523 | 0.12 | Why? |
| Time Factors | 5 | 2020 | 31397 | 0.12 | Why? |
| Renal Insufficiency | 1 | 2019 | 810 | 0.11 | Why? |
| Thrombosis | 4 | 2021 | 7504 | 0.11 | Why? |
| Mortality | 2 | 2017 | 7132 | 0.10 | Why? |
| Hydrocortisone | 1 | 2020 | 1790 | 0.10 | Why? |
| Neoplasm Staging | 1 | 2017 | 1999 | 0.10 | Why? |
| Anemia | 1 | 2017 | 789 | 0.10 | Why? |
| Anticoagulants | 2 | 2021 | 9563 | 0.10 | Why? |
| Registries | 3 | 2019 | 12327 | 0.10 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.10 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.10 | Why? |
| Humans | 34 | 2021 | 930598 | 0.10 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.09 | Why? |
| Surveys and Questionnaires | 4 | 2020 | 43792 | 0.09 | Why? |
| Risk | 2 | 2018 | 5288 | 0.09 | Why? |
| Critical Pathways | 1 | 2018 | 1587 | 0.09 | Why? |
| Prospective Studies | 6 | 2019 | 43301 | 0.09 | Why? |
| Middle Aged | 14 | 2021 | 270681 | 0.09 | Why? |
| Survival Analysis | 2 | 2021 | 7592 | 0.09 | Why? |
| Trauma Centers | 1 | 2016 | 1195 | 0.09 | Why? |
| Early Termination of Clinical Trials | 2 | 2020 | 1256 | 0.08 | Why? |
| Plasma | 1 | 2017 | 1809 | 0.08 | Why? |
| Immunoglobulins, Intravenous | 1 | 2019 | 2705 | 0.08 | Why? |
| Clinical Trials as Topic | 4 | 2020 | 7330 | 0.08 | Why? |
| Thrombocytopenia | 1 | 2019 | 2093 | 0.08 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.08 | Why? |
| Practice Guidelines as Topic | 3 | 2020 | 15421 | 0.08 | Why? |
| Bacteremia | 1 | 2017 | 1372 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.07 | Why? |
| Aged | 10 | 2021 | 215776 | 0.07 | Why? |
| Respiration, Artificial | 5 | 2021 | 22116 | 0.07 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 2426 | 0.07 | Why? |
| Bias | 2 | 2021 | 1109 | 0.07 | Why? |
| Blood Coagulation | 1 | 2017 | 2768 | 0.07 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.07 | Why? |
| Medical Oncology | 1 | 2020 | 3826 | 0.06 | Why? |
| Male | 13 | 2021 | 367725 | 0.06 | Why? |
| Cohort Studies | 2 | 2017 | 36005 | 0.06 | Why? |
| Female | 13 | 2021 | 380317 | 0.06 | Why? |
| Adult | 10 | 2021 | 244371 | 0.06 | Why? |
| Risk Factors | 5 | 2018 | 71621 | 0.06 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.06 | Why? |
| Practice Patterns, Physicians' | 2 | 2019 | 4927 | 0.06 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2016 | 9537 | 0.05 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 8811 | 0.05 | Why? |
| Venous Thromboembolism | 1 | 2018 | 4273 | 0.05 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.05 | Why? |
| Selection Bias | 1 | 2020 | 201 | 0.05 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.05 | Why? |
| Bortezomib | 1 | 2019 | 125 | 0.05 | Why? |
| Travel | 1 | 2017 | 7220 | 0.04 | Why? |
| Severity of Illness Index | 4 | 2020 | 48226 | 0.04 | Why? |
| Transplantation, Autologous | 1 | 2019 | 364 | 0.04 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.04 | Why? |
| Double-Blind Method | 2 | 2019 | 5988 | 0.04 | Why? |
| Hemoglobinuria, Paroxysmal | 1 | 2017 | 116 | 0.04 | Why? |
| Ventilator Weaning | 1 | 2021 | 536 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2017 | 673 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2019 | 1115 | 0.04 | Why? |
| Microcephaly | 1 | 2017 | 181 | 0.04 | Why? |
| Oligopeptides | 1 | 2019 | 576 | 0.04 | Why? |
| Treatment Failure | 1 | 2021 | 2106 | 0.04 | Why? |
| Blood Donors | 2 | 2020 | 2956 | 0.04 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.04 | Why? |
| Transplantation, Homologous | 1 | 2017 | 757 | 0.03 | Why? |
| Child | 3 | 2020 | 70012 | 0.03 | Why? |
| Infectious Disease Medicine | 1 | 2017 | 311 | 0.03 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.03 | Why? |
| Thrombotic Microangiopathies | 1 | 2017 | 335 | 0.03 | Why? |
| Aedes | 1 | 2017 | 380 | 0.03 | Why? |
| Factor Xa Inhibitors | 1 | 2018 | 490 | 0.03 | Why? |
| Hematologic Diseases | 1 | 2020 | 614 | 0.03 | Why? |
| Biomarkers | 1 | 2016 | 23361 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2019 | 1262 | 0.03 | Why? |
| Shock | 1 | 2020 | 1868 | 0.03 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2019 | 2437 | 0.03 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.03 | Why? |
| Disease Outbreaks | 2 | 2017 | 27595 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2016 | 1654 | 0.03 | Why? |
| Retrospective Studies | 3 | 2018 | 105322 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2019 | 3395 | 0.02 | Why? |
| Neoplasm Recurrence, Local | 1 | 2016 | 1063 | 0.02 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.02 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Dexamethasone | 1 | 2019 | 2055 | 0.02 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.02 | Why? |
| Communicable Disease Control | 1 | 2017 | 29620 | 0.02 | Why? |
| Research | 1 | 2020 | 2115 | 0.02 | Why? |
| Disease Transmission, Infectious | 2 | 2020 | 9044 | 0.02 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Bacterial Infections | 1 | 2019 | 2229 | 0.02 | Why? |
| Incidence | 2 | 2017 | 25622 | 0.02 | Why? |
| Survival Rate | 1 | 2019 | 9206 | 0.02 | Why? |
| Cardiac Surgical Procedures | 1 | 2018 | 1931 | 0.02 | Why? |
| Zika Virus | 1 | 2017 | 1924 | 0.02 | Why? |
| Research Design | 1 | 2020 | 5830 | 0.02 | Why? |
| Animals | 3 | 2017 | 78931 | 0.02 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.02 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.02 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.01 | Why? |
| Virus Diseases | 1 | 2019 | 3779 | 0.01 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.01 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.01 | Why? |
| United Kingdom | 1 | 2019 | 18046 | 0.01 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.01 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.01 | Why? |
| Infant | 1 | 2019 | 30274 | 0.01 | Why? |
| Prognosis | 1 | 2019 | 32490 | 0.01 | Why? |
| Child, Preschool | 1 | 2019 | 36283 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2019 | 21571 | 0.01 | Why? |
| Vaccination | 1 | 2019 | 19050 | 0.01 | Why? |
| Neoplasms | 1 | 2020 | 17251 | 0.01 | Why? |
| Public Health | 1 | 2017 | 16359 | 0.01 | Why? |
| Adolescent | 1 | 2019 | 86841 | 0.01 | Why? |
| Young Adult | 1 | 2019 | 93724 | 0.01 | Why? |
McQuilten's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(177)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(1276)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_